Abstract:Background: Previous studies have suggested that the gut microbiota (GM) is closely associated with the development of autoimmune cholestatic liver disease (ACLD), but limitations, such as the presence of confounding factors, have resulted in a causal relationship between the gut microbiota and autoimmune cholestatic liver disease that remains uncertain. Thus, we used two-sample Mendelian randomization as a research method to explore the causal relationship between the two. Methods: Pooled statistics of gut microbiota from a meta-analysis of genome-wide association studies conducted by the MiBioGen consortium were used as an instrumental variable for exposure factors. The Pooled statistics for primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) were obtained from the R9 version of the FinnGen database (https://r9.finngen.fi/). Inverse-variance Weighted (IVW), cML-MA, MR-Egger regression, Weighted median (WME), Weighted mode (WM), and Simple mode (SM) were used to detect the association between intestinal flora and the causal relationship between intestinal flora and ACLD, in which IVW method was dominant, was assessed based on the effect indicator dominance ratio (odds ratio, OR) and 95% confidence interval (CI). Sensitivity analysis, heterogeneity test, gene pleiotropy test, MR pleiotropy residual sum and outlier test (MR-PRESSO) were combined to verify the stability and reliability of the results. Reverse Mendelian randomization analysis was performed on gut microbiota and found to be causally associated with ACLD. Results: The IVW results showed that the relative abundance of the genus Clostridium innocuum group, genus Butyricicoccus , and genus Erysipelatoclostridium was negatively correlated with the risk of PBC, that is, increased abundance reduced the risk of PBC and was a protective, and the relative abundance of the genus Eubacterium hallii was positively correlated with the risk of PSC, which is a risk factor for PSC. Family Clostridiaceae1 and family Lachnospiraceae were negatively correlated with the risk of PSC, which is a protective factor for PSC. Conclusion: This study found a causal relationship between gut microbiota and ACLD. This may provide valuable insights into gut microbiota-mediated pathogenesis of ACLD. It is necessary to conduct a large-sample randomized controlled trial (RCT) at a later stage to validate the associated role of the relevant gut microbiota in the risk of ACLD development and to explore the associated mechanisms.

The Causality Between Gut Microbiome and Liver Cirrhosis: a Bi-Directional Two-Sample Mendelian Randomization Analysis

The causal relationship between gut microbiota and end-stage liver disease: a bidirectional Mendelian randomization analysis

Causal Relationship Between Gut Microbiota and Liver Cirrhosis: 16S rRNA Sequencing and Mendelian Randomization Analyses

Roles of Human Gut Microbiota in Liver Cirrhosis Risk: A Two-Sample Mendelian Randomization Study.

Causal associations between gut microbiota and Cholestatic liver diseases: a Mendelian randomization study

Association Between Gut Microbiota and NAFLD/NASH: a Bidirectional Two-Sample Mendelian Randomization Study

Association between gut microbiota and hepatocellular carcinoma and biliary tract cancer: A mendelian randomization study

Dissecting the association between gut microbiota and liver cancer in European and East Asian populations using Mendelian randomization analysis

Causal associations between human gut microbiota and cholelithiasis: a mendelian randomization study

Causal relationships between the gut microbiota, inflammatory cytokines, and alcoholic liver disease: a Mendelian randomization analysis

Association of Gut Microbiome and Primary Liver Cancer: A Two‐sample Mendelian Randomization and Case–control Study

Investigating causal associations among gut microbiota, metabolites, and liver diseases: a Mendelian randomization study

Association between gut microbiota and autoimmune cholestatic liver disease, a Mendelian randomization study

Causal associations between gut microbiota and primary biliary cholangitis: a bidirectional two-sample Mendelian randomization study

The relationship between diverticular disease of intestine and cirrhosis: a two-sample mendelian randomization study

Functional gene arrays-based analysis of fecal microbiomes in patients with liver cirrhosis

Causality Between Gut Microbiota and Inflammatory Bowel Disease: A Bidirectional Mendelian Randomization Study

A Bidirectional Two-Sample Mendelian Randomization Using the Gut Microbiota to Reveal Potential Therapeutic Targets for Primary Sclerosing Cholangitis.

Causal impact of gut microbiota on five liver diseases: insights from mendelian randomization and single-cell RNA sequencing

Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology

Characterization of Fecal Microbial Communities in Patients with Liver Cirrhosis.